A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Study sponsor: Ultragenyx Pharmaceutical Inc · RARE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-10-01Actual
Enrollment · participants112Actual
Source updated2023-07-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.